Quantum BioPharma Completes Phase 1 Trial for Multiple Sclerosis Therapy Lucid-MS
Quantum BioPharma announces completion of Phase 1 clinical studies for Lucid-MS, a therapy targeting myelin repair in multiple sclerosis, and submission of an IND application to the FDA.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has taken a significant step forward in the development of a potential treatment for multiple sclerosis (MS), a chronic neurological disease affecting over 2.8 million people worldwide, including approximately 1 million in the United States. The company announced the completion of Phase 1 clinical studies for Lucid-MS, its patented therapeutic candidate designed to target demyelination and provide neuroprotection, aiming to address the loss of mobility and function that plagues MS patients.
The Phase 1 trial, conducted in healthy volunteers, demonstrated that Lucid-MS has a favorable safety profile and was generally well tolerated. This milestone is crucial as current MS treatments primarily focus on reducing inflammation and relapse frequency but often fail to address the underlying neurodegeneration and myelin damage that drive long-term disease progression. Lucid-MS is specifically designed to protect or restore myelin integrity, an unmet need in MS therapy.
Building on these results, Quantum BioPharma reached another key milestone in April 2026 with the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Lucid-MS. The IND submission is a critical regulatory step that, if cleared, will allow the company to proceed with Phase 2 clinical trials to further evaluate the therapy's efficacy in MS patients.
Multiple sclerosis is a chronic autoimmune and neurodegenerative disease in which the immune system attacks myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. As myelin deteriorates, communication between nerves becomes disrupted, leading to symptoms that can include loss of mobility and control of one's body. The disease's progressive nature and unpredictable course make it challenging for both patients and clinicians, with no cure currently available.
Quantum BioPharma's Lucid-MS program is built around this unmet medical need. The company's focus on neuroprotection and myelin repair represents a potential paradigm shift in MS treatment, moving beyond immune modulation to directly address the root cause of disability progression. If successful, Lucid-MS could offer new hope to the millions of MS patients who continue to experience worsening disability despite existing therapies.
For more information on Quantum BioPharma and its developments, visit the company's newsroom at https://ibn.fm/QNTM. Readers are encouraged to review the full terms of use and disclaimers available at http://IBN.fm/Disclaimer.